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Phenytoin (PHT) has been the most widely used medication to treat both partial and generalized seizures. However, over the past
twenty years, a variety of new compounds have been released with comparable efficacy, fewer adverse effects, and more predictable
pharmacokinetic properties. We surveyed neurologists and epileptologists to determine current practice patterns relating to the
use of PHT using an online survey instrument. A total of 200 responses were obtained though response rates for each survey
question varied. Of the respondents, 78.1% were epilepsy specialists; 60% were adult practitioners; and the remainder saw either,
only children or both adults and children. For new onset partial seizures only 10 respondents said PHT would be their first or
second choice, while 45% reported that they would not consider PHT. This study shows that in the era of newer medications, the
role of PHT has been placed in the category of a reserve medication in intractable epilepsy.
1. Introduction
Phenytoin (PHT) was first synthesized in 1908 at the Uni-
versity of Kiel in Germany. Anticonvulsant properties of this
compound were first described by Merritt and Putnam in
1938, and PHT was brought to market by Parke Davis later
that year [1–3]. Since its introduction as an anticonvulsant,
PHT, marketed under the trade-name Dilantin, has been the
predominant medication for the treatment of epilepsy for
over 7 decades. The introduction of an IV formulation and
later an IV pro-drug formulation (fosphenytoin) led to this
medication being used as the first choice in the treatment
of status epilepticus and acute repetitive seizures. However,
with the introduction of numerous newer antiepileptic med-
ications, with fewer adverse effects, better pharmacokinetic
profiles, better patient tolerability, and proven efficacy, the
role of phenytoin as a treatment of choice in epilepsy has
become uncertain.
The aim of the current study was to determine practice
patterns among neurologists and epileptologists with regard
totheuseofPHTinthetreatmentofepilepsy.Wealsosought
to understand the reasons why physicians prescribed (or
did not prescribe) this important medication. We therefore
surveyedneurologistsandepileptologiststoascertaincurrent
practice regarding the use of PHT in treating persons with
epilepsy.
2. Methods
Anonlinesurveywithelevenquestionswascreatedusingthe
website http://www.surveymonkey.com/. A list of questions
i nt h es u r v e y( a n di n d i v i d u a lr e s p o n s er a t e sf o re a c hq u e s -
tion) is found in Table 1. Questions were designed to capture
demographic and clinical characteristics of respondents as
well as practice patterns. A hyperlink to the survey was
emailed on two successive occasions, to 1650 members of the
American Epilepsy Society (AES) who received the link in
the fortnightly email newsletter of the society. A total of 59
responses were obtained in this manner with a response rate
of 3.5%. Subsequently, a link to the survey was emailed to2 ISRN Neurology
Table 1: Survey questions and response rates.
Questions Number of responses
Demographic information questions
Is your primary specialty neurology or
epilepsy?
200
Do you see adult patients, pediatric patients,
or both?
200
What best describes the geographical
location of your clinical practice?
199
Clinical practice information questions
Do you receive referrals for the management
and further evaluation of intractable
epilepsy?
198
On average, over the course of a week, how
many patients with epilepsy do you see, as
outpatients?
198
What percentage of your patients have
refractory epilepsy?
199
Questions pertaining to use of phenytoin
On average, in how many patients, per week,
do you initiate phenytoin as anticonvulsant
therapy?
194
H o wm a n yp a t i e n t sd oy o us e eo nar e g u l a r
basis that are already on phenytoin
anticonvulsant therapy?
198
In your opinion, what choice is phenytoin
for a patient with new onset partial seizures?
185
On average, how many patients have you
seen with side effects from phenytoin that
have led to the discontinuation of the
medication?
188
In your opinion, how effective is phenytoin
in controlling seizures?
199
400randomlychosenmembersoftheAES,withmembership
andemailcontactinformationobtainedusingtheAESonline
membershipdatabase.Memberswhoidentifiedthemselvesas
neurosurgeons, pharmacists, psychiatrists, and psychologists
were excluded. One hundred and thirty-nine responses were
obtained (response rate: 34.75%), making for a total of
200 responses, though not all responders answered every
question on the survey.
All statistical analyses were performed using the Fisher
exact test to determine levels of statistical significance for
dichotomousvariables.Giventhatthestudyinvolvedasurvey
instrument, human subjects committee approval was not
required at the University of Louisville.
3. Results
Two hundred individuals responded to the online sur-
vey. One hundred and sixty-two described themselves as
epileptologists, thirty-five as neurologists; three respondents
included a pediatrician, a pharmacist, and the director of a
neurophysiology school. One hundred and twenty reported
primarily seeing adult patients, fifty-three saw only children,
and twenty-seven reported seeing both adults and children.
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Figure 1: Geographical distribution of respondents (percentages).
Four-fifth of the responses came from respondents who
described their geographical area of practice as the United
States; the rest of the responses were from Europe and Asia.
A more detailed description of geographical distribution of
respondents may be found in Figure 1.
With regard to clinical practice, virtually all respondents
(𝑛 = 192,97.4%)sawpatientswithintractableepilepsy.Sixty-
one respondents reported seeing between 11–20 outpatients
with epilepsy per week, 57 saw between 20 and 40 a week, 55
saw up to 10 per week while, 25 saw more than 40 patients
a week in clinic. Sixty-one respondents noted that between
50%–75% of their outpatients had refractory epilepsy while
77 reported that 25%–50% of their patients had refractory
epilepsy. Only 16 respondents stated that more than 75% of
their outpatients had refractory seizures; 45 saw less than
25% with refractory seizures. Respondents were hesitant in
their decision to initiate PHT for their outpatients with 193
respondents reporting that they started PHT for epilepsy
in less than 5 outpatients, on a weekly basis. Only one
respondentinitiatedmorethan10patientsonPHTinaweek.
One hundred and fifty-eight respondent noted seeing up to 5
patientsaweekwhoalreadywereonPHT,thirtysawbetween
6–10 per week, and ten reported seeing greater than 10 per
week already on PHT.
Onlyonerespondentstatedthathe/shewouldusePHTas
first choice for newly diagnosed localization related epilepsy,
with 45% unwilling to even consider this medication. More
information in this regard can be found in Figure 2.I n t e r -
estingly, only one respondent did not think that PHT was
effective in treating epilepsy with 129 stating that PHT was
very effective in treating seizures and 69 stated that PHT was
somewhat effective. Thirty-seven respondents reported that
up to 20 patients a year discontinued PHT, 46 reported that
gr ea terthan20pa tien tsayearsto p pedPHT ,allo nacco un to f
side effects.
Two respondents, both pediatric neurologists, individu-
a l l ye m a i l e du st h e i ru n s o l i c i t e do p i n i o n sa b o u tt h er o l eo f
PHT in current clinical practice. One pointed out that (there
is) “virtually no role for maintenance phenytoin in pediatric
epilepsymanagement.Ihavebeenpracticingfor25yearsand
cannotrememberusingitexceptforaveryshorttimeinearly
post-traumatic seizures [in severe head injury].” The second
respondent opined that “most ED physicians, primary careISRN Neurology 3
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Figure 2: What choice is Phenytoin for a patient with new onset
localization related epilepsy?
docs (sic), and patient families do not understand zero-order
kinetics and the need to make changes in small increments.
Consequently, the kids on phenytoin bounce in and out of
EDs with toxicity or breakthrough seizures.” The respondent,
however, felt that there was a special role for PHT in treating
s e i z u r e st h a ta r i s ei nt h ef r o n t a ll o b e .
To improve statistical power for testing of significance,
we collapsed respondent choices of PHT of first to fourth
choice into one group and those who would not use PHT
into a second group. Using Fischer’s exact test, we compared
respondents’ choices for epilepsy treatment between those
who treated adults with epilepsy as compared to those who
treated children or children and adults. Fifty-eight percent of
adult practitioners reported that PHT was among their first
four choices for initial therapy of localization related epilepsy
as compared to 43% of pediatric practitioners. The trend
was nonsignificant (𝑃 = 0.1). Similarly, we also examined
differences in choosing PHT as a treatment for localization
epilepsy between physicians who saw only adult patients
with epilepsy on the one hand (𝑛 = 110)a n dt h o s ew h o
saw children exclusively and those who saw both adults and
children on the other hand (𝑛=8 0 ). The difference again
was nonsignificant (𝑃 = 0.38). Finally, we again examined
difference between those who practiced in the United States
(𝑛 = 162) as compared to those who practiced elsewhere in
the world (𝑛=3 7 ); the difference was again nonsignificant
(𝑃 = 0.59).
4. Discussion
Prior to the introduction of PHT in 1938, the principal
pharmacological mechanisms of treating seizures were phe-
nobarbital, borax, and the bromides. By 1940, PHT became
the most important and frequently used drug to treat
epilepsyasnotedbytheAnnualReviewofEpilepsypublished
that year [4] .P H Th a sb e e nt h efi r s tc h o i c ed r u gi nt h e
treatment of epilepsy since then, though the introduction
of carbamazepine (CBZ) and valproate (VPA) in the 1970s
led to these drugs becoming first choice medications for
partial onset (CBZ) and childhood epilepsies (VPA) [5].
Between 1989 and 1994, five new anticonvulsants were intro-
duced: felbamate, vigabatrin, gabapentin, lamotrigine, and
oxcarbazepine. Between 1994 and 2009 a further nine new
medications came to market; the most important of which
are topiramate and levetiracetam [5]. Of these medications,
oxcarbazepine, lamotrigine, levetiracetam, and topiramate
have become very important choices for clinicians when
prescribing anticonvulsants in large part due to favorable
pharmacokinetics, fewer adverse events, and better patient
tolerability.
Very few studies have examined current anticonvulsant
prescribing trends by clinicians. Using a large American
database of patients with a new diagnosis of epilepsy, based
onMedicareandVeteransAffairsdata,Hopeetal.foundthat
PHT was the initial AED in two thirds of all patients, in the
years between 1999 and 2004 [6]. In Australia, Hollingworth
andEadiefoundthat,despitetheintroductionofanumberof
newer medications, the most commonly used medications,
between 2002 and 2007, were PHT, CBZ, and VPA with
the latter being the most popular [7]. In Taiwan, in 2004,
PHT was the second most popular medication after CBZ for
epilepsymonotherapy[8].InItaly,priorto2005,phenobarbi-
tal,carbamazepine,andphenytoinwerethemajorAEDsused
in the treatment of epilepsy. Following 2004, gabapentin was
reported, in a large prescribing database study, to be the most
popular AED. The authors of this study report that in more
recentyears,newerAEDshavebecomemorefrequentlyused
in older patients [9]. A regional Italian study reported a 25%
increase in prescriptions for newer AEDs between 2004 and
2005 [10].
Occasional surveys have examined the issue of physician
c h o iceso fa n tico n vulsa n ts.B urn eoa n dM cLac hla ns urv ey ed
Canadian neurologists, asking what medication they would
use given a variety of clinical situations. VPA was the
first choice for generalized epilepsy in males, lamotrigine
for females. CBZ was the first choice for the treatment of
localization related epilepsy, lorazepam for status epilepticus
[11]. In a survey of opinion leaders in epilepsy, Karceski et al.
found that PHT was not a first choice medication in the
t r e a t m e n ti na n ys e i z u r et y p ei na d o l e s c e n t sa n da d u l t s .Th e
authors did not however seek an opinion on the first choice
intreatingstatusepilepticus[12]. A French survey found that
P H Tw a sn o ti nt h et o pt h r e ea n dm o s to ft e nt o pfi v ec h o i c e
of epileptologists for a range of epileptic syndromes, from
absence seizures to localization related epilepsy [13].
Our study is the first to examine the opinions of neurol-
ogists and epileptologists with regard to the continued use of
PHT in treating epilepsy. The majority of respondents in the
survey were from the United States, which is not surprising
given that the survey was distributed through the American
Epilepsy Society. However, respondents practiced in every
continent excluding Africa. A slight majority were adult
practitioners, with 40% seeing either children alone or both
adults and children; almost all respondents received referrals
for the evaluation of intractable epilepsy. The majority of4 ISRN Neurology
respondents saw between 20–40 patients with epilepsy on
a weekly basis. A significant number of these patients had
intractable epilepsy.
Forty-five percent of respondents stated that they would
not consider using PHT in a patient with newly diagnosed
localizationrelatedepilepsy.Onlyonerespondentwaswilling
to use PHT as a first choice medication for this condition.
Thisstudyshowsthatthevastmajorityofrespondentsbelieve
that PHT is effective in treating seizures. This is in line with
evidence based guidelines which have demonstrated that the
highest level of evidence exists to support the use of PHT
as initial monotherapy for adults with localization related
epilepsy [14]. However, virtually all respondents had seen
at least 10 patients annually who had had adverse events
related to PHT that lead to discontinuation of this AED. The
vast majority also reported initiating only a small number of
patients with newly diagnosed localization related epilepsy
with PHT therapy.
Very importantly our survey found no significant differ-
ences across a variety of different physician groups regarding
prescribing choices using PHT for new onset localization
related epilepsy. Historically, PHT has been more important
in treating epilepsy in adults, but in this study, no significant
differences emerged between physicians who saw adults
only and those who saw children. Again, no differences
emerged between neurologists and epileptologists in this
regard. Finally, physician opinions did not differ between
thosewhopracticedintheUnitedStatesandthoseoutsidethe
US.Thisisveryimportant,asinmanynationswithsocialized
systemsofhealthcare,theprimaryfocusremainsonreducing
costs and as an older medication with many generic forms,
PHT is relatively inexpensive.
The number of PHT side effects, both acute and chronic,
the narrow therapeutic index, and poor patient tolerability
compare poorly with newer medications like levetiracetam
and lamotrigine which have much fewer side effects and a
broadtherapeuticindex.Theremaystillremainanimportant
role for PHT in the treatment of status epilepticus with a
recentEuropeantreatmentguidelinerecommendingIVPHT
as treatment of choice for convulsive and nonconvulsive SE
that does not respond to lorazepam; this recommendation
was supported by high quality evidence [14]. We did not
examine clinician opinions regarding treatment of SE with
PHT in this survey.
As in any observation made based on surveys, our
findings need to be interpreted in the context of low recruit-
ment of physicians completing the survey, and the intrinsic
bias that exists when summarizing findings from surveys.
Nevertheless, our survey therefore demonstrates that while
PHT is an excellent medication for controlling seizures, it is
no longer a frontline medication in treating epilepsy due to
s e v e r a lo t h e ri m p o r t a n tf a c t o r s .Th er o l eo fP H Tm o s tl i k e l y
will be that of a reserve medication for intractable epilepsy.
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